Instrument NamePfizer IncInstrument Symbol(PFE-N)

Instrument ExchangeNYSE

Put your money to work by investing in these three high-quality dividend stocks.

This ambitious biotech aims to launch 15 products over the coming five years.

Andrew Pyle, portfolio manager and senior investment advisor at CIBC Wood Gundy, is increasing his exposure to China, India, Japan and the U.S.

/CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for VELSIPITY™. A once-daily oral treatment, VELSIPITY is...

These two pharma stocks have followed distinct paths of late. Which is the better investment?

This Vanguard growth fund is home to some of the world's most innovative companies.

/CNW/ - During National Immunization Awareness Week, Pfizer Canada and McMaster University are proud to announce a significant project aimed at addressing...

A little up-front investment can go a long way with these three stocks.

The answer to that question will either make you wince or smile.

A modest amount of money can go a long way in the stock market when it's put to work in time-tested businesses with well-defined competitive advantages.

/CNW/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is...

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

The pharmaceutical giant is laying the groundwork for its next heyday.

The average yield from these stocks is more than five times the market average.

These three stocks are bargains with great dividends.

Is there still too much risk surrounding this business?

These dividend payers have a long history of steady dividend payout raises, and they both offer yields above 6% at recent prices.

When something seems too good to be true it might not be.

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Is this top healthcare stock a good buy for the long run?

We've also got a look at 3M's spinoff, gold prices, and the beef industry.

A rate cut would likely be a boon for these two ultra-high yield dividend stocks.

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

These companies are close to launching new products that could supercharge revenue.